Kabaye Kumela Goro

Kabaye Kumela Goro

Auto-generated profile, based on publicly available information

Kabaye Kumela Goro

Department of Clinical Pharmacy, School of Pharmacy, Institute of Health, Jimma University, Jimma, Ethiopia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2019 in BioMed Research International
Verified
Journal Article
Open access
PDF file
KGKabaye Kumela Goro
Kabaye Kumela Goro
AWAmare Desalegn Wolide
Amare Desalegn Wolide
FDFantu Kerga Dibaba
Fantu Kerga Dibaba
FFFanta Gashe Fufa
Fanta Gashe Fufa
Aster Wakjira GaredoAster Wakjira Garedo
Aster Wakjira Garedo
EBEshetu Mulisa Bobasa
Eshetu Mulisa Bobasa
Background. There is an alarming rise of chronic kidney disease (CKD) prevalence globally, which is associated with significant morbidity and mortality necessitating special attention as one of the major public health problems. The burden of CKD disproportionately impacts low-income countries like Ethiopia where hypertension and diabetes mellitus, the two most important risk factors for CKD growth rate, are greatest. Objective. The aim of this study is to assess patient awareness, prevalence, and risk factors of chronic kidney disease among hypertensive and diabetes mellitus patients. Methods. Hospital based cross-sectional study design was conducted at Jimma University Medical Center among adult (≥18 years) hypertensive and diabetes mellitus patients. Informed written consent was obtained from each participant and data was collected by interview and chart review; blood and urine samples were collected for CKD screening. Glomerular filtration rate (GFR) was estimated from serum creatinine using CKD epidemiology collaboration (CKD-EPI) equation, and CKD was defined using estimated GFR (e-GFR) and albuminuria. Multivariate logistic regression was used to identify independent predictors of CKD and p-value 150 mg/dl, long duration of hypertension, ACEIs nonusers, and poor knowledge about CKD.

20 October 2019 in International Journal of Nephrology
Verified
Journal Article
Open access
PDF file
Aster Wakjira GaredoAster Wakjira Garedo
Aster Wakjira Garedo
EBEshetu Mulisa Bobasa
Eshetu Mulisa Bobasa
AWAmare Desalegn Wolide
Amare Desalegn Wolide
FDFantu Kerga Dibaba
Fantu Kerga Dibaba
FFFanta Gashe Fufa
Fanta Gashe Fufa
KGKabaye Kumela Goro
Kabaye Kumela Goro
Background. There is an alarming rise of chronic kidney disease prevalence globally associated with significant morbidity and mortality necessitating special attention as one of the major growing public health problems. Medication-related problems are common in hospitalized patients including chronic kidney disease and may lead to increase hospital stay and health care cost and augment the risk of morbidity and mortality. Objective. To determine prevalence of medication-related problems and associated factors among chronic kidney disease patients admitted to Jimma University Medical Center from April to September 2018. Methods. A hospital-based prospective observational study was conducted among 103 chronic kidney disease patients admitted to Jimma University Medical Center from April to September 2018. Data regarding patient characteristics, medications, diagnosis, length of hospitalization, and laboratory results were collected through review of patients’ medical charts. Data were analyzed by using Statistical Package for the Social Sciences (SPSS) version 21.0. Univariate and multivariate logistic regression was utilized to assess the associations between dependent and independent variables. Statistical significance was considered at p value <0.05. Results. Out of 103 chronic kidney disease patients, 81 (78.6%) of patients had MDRs, on average 1.94 ± 0.873 per patient. The rate of overall MRPs was 30.95 per 100 medication orders. The most common MRPs among CKD patients were need additional drug therapy (62 (31%)), nonadherence (40 (20%)), and dose too low (36 (18%)). The most common cause of need additional drug therapy (52 (26%)) was untreated medical conditions; nonadherence (19 (9.5%)) was mostly due to that the patient/caregiver forgets to take/give the medication, and dose too low (29 (14.5%)) was mostly due to that the dose is too low to produce the desired response. Polypharmacy (AOR = 4.695, 95% CI: 1.370–16.091), number of comorbidities (AOR = 3.616, 95% CI: 1.015–1.8741), and stage of CKD (AOR = 3.941, 95% CI: 1.221–12.715) were independent predictors for MRPs. Conclusions. We have demonstrated that medication-related problems are high among chronic kidney disease patients. Marital statuses, stage of CKD, polypharmacy, and comorbidity were independent predictors for MRPs. Interdisciplinary health professionals should work to decrease the high prevalence of MRPs among chronic kidney disease patients.

20 August 2019 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
MMMoa Megersa
Moa Megersa
TJTilahun Tolossa Jima
Tilahun Tolossa Jima
KGKabaye Kumela Goro
Kabaye Kumela Goro
This paper presents a review of relevant medicinal plants used for toothache treatment in Ethiopia. This finding is based on a review of the literature published in scientific journals. A total of 130 medicinal plants, distributed in 117 genera and 62 families, are reported in the reviewed literature. Of the 130 species of medicinal plants reported in the literature, ninety-two (70.7) were obtained from the wild whereas twelve (9.2) were from home gardens. Shrubs (34.6) were the primary source of medicinal plants, followed by herbs (30). The Asteraceae came out as a leading family with 12 medicinal species while the Fabaceae followed with nine. Some findings include the predominance of root material used (31), followed by leaves (29). This study demonstrates the importance of traditional medicines in the treatment of toothache in Ethiopia. It is essential for the health of users to phytochemically demonstrate the effects of medicinal plants for their possible therapeutic applications. Hence, future phytochemical and pharmaceutical studies should give due consideration on frequently reported medicinal plants in order to produce natural drugs that could be effective in toothache treatment and without side effects.

13 October 2020 in Canadian Respiratory Journal
Verified
Journal Article
Open access
PDF file
TATeshale Ayele
Teshale Ayele
TMTemesgen Mulugeta
Temesgen Mulugeta
DBDula Dessalegn Bosho
Dula Dessalegn Bosho
KGKabaye Kumela Goro
Kabaye Kumela Goro
GNGetandale Zeleke Negera
Getandale Zeleke Negera
Background. The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in an unprecedented public health challenge worldwide. Despite urgent and extensive global efforts, the existing evidence is inconclusive regarding the medications used for the treatment of COVID-19. Purpose. To generate an up-to-date evidence for the clinical safety and efficacy of hydroxychloroquine (HCQ) with or without azithromycin (AZ) among patients treated for COVID-19. Data Source. PubMed, Cochrane CENTRAL, LITCOVID, Web of Science, SCOPUS, BioRxiv, Embase, MedRxiv, and Wiley online library were searched from 2019/12/30 to 2020/05/23. Study Selection. Three investigators assessed the quality of the studies. Data Extraction. Data about study characteristics, effect estimates, and the quality of the studies were extracted by two independent reviewers and cross-checked by the third reviewer. Data Synthesis. The data of 6,782 (HCQ group, 3623; HCQ + AZ group, 1,020; control group, 2139) participants were included. HCQ was compared with standard care for virologic efficacy, disease progression, mortality, and adverse effects. HCQ was also compared with HCQ + AZ for QTc prolongation, admission to the intensive care unit, and mortality. The study found HCQ did not alter the rate of virologic cure (OR = 0.78; 95% CI: 0.39-1.56) and the risk of mortality (OR = 1.26; 95% CI: 0.66-2.39). The pooled prevalence for mortality was 5.8% (95% CI: 0.9%-10.8%). Moreover, HCQ did not impact disease progression (OR = 0.9; 95% CI: 0.36-2.29) but resulted in a higher risk of adverse effects (OR = 2.35; 95% CI: 1.15-4.8). HCQ was also compared against HCQ + AZ, and no difference was observed in QTc prolongation above 500 ms (OR = 1.11; 95% CI: 0.54-2.28), admission to the intensive care unit (OR = 0.92; 95% CI: 0.52-1.63), and mortality (OR = 0.88; 95% CI: 0.55-1.43). However, in the analysis of single-arm studies, about 11.2% (95% CI: 7.0%-15.5%) of patients have developed an absolute increase of QTc greater than 500 ms, and 4.1% (95% CI: 1.1%-7.1%) of patients discontinued their medication. Conclusion. This meta-analysis and systematic review, which included a limited number of poorly designed studies of patients with COVID-19, revealed HCQ is intolerable, unsafe, and not efficacious. Similarly, HCQ + AZ combination was not different from HCQ alone in curbing mortality and ICU admission.

20 August 2019 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
AZAmeha Zewudie
Ameha Zewudie
TNTadesse Nigussie
Tadesse Nigussie
YMYitagesu Mamo
Yitagesu Mamo
KKKabaye Kumela
Kabaye Kumela
The aim of this study was to assess determinants of poorly controlled asthma among asthmatic patients on follow up at Jimma University Medical Center, Southwest Ethiopia. A facility based case control study involving chart review and patient interview was conducted from April 01/2017 to May 30/2017. Consecutive sampling method was used to select 121 cases and 121 controls. Descriptive statistics were used to present socio demographic data and drug prescription pattern while logistic regression was used to identify predictors of poorly controlled asthma. From a total of 242 studied asthmatic patients, 52.9% of controls and 44.6% of cases were males. Poor knowledge about asthma [Adjusted odd ratio(AOR) = 7.30; 95% confidence interval (CI) 1.72–30; P = 0.007], negative attitude about asthma [AOR = 5.10; 95% CI 1.40–18.7; P = 0.014], moderate asthma [AOR = 13.47; 95% CI 2.69–47.23; P = 0.002] and non-adherence to inhaled corticosteroid (ICS) [AOR = 8.52%; 95% CI 2.41–13.45; P = 0.001] were determinants of poorly controlled asthma.

24 April 2019 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YNYirga Legesse Niriayo
Yirga Legesse Niriayo
KKKabaye Kumela
Kabaye Kumela
KGKidu Gidey
Kidu Gidey
MAMulugeta Tarekegn Angamo
Mulugeta Tarekegn Angamo
Background. Optimal use of angiotensin-converting enzyme inhibitors (ACEIs) is crucial to improve the treatment outcome in heart failure patients. However, little is known about the optimal use of ACEIs among heart failure patients in our setting. Therefore, our study aimed to investigate the utilization and optimal dosing of ACEIs and associated factors in heart failure patients. Method. A cross-sectional study was conducted on randomly selected patients with heart failure between February 2016 and June 2016 at ambulatory care clinic of Jimma University Medical Center, Ethiopia. Data were collected through patient interview and review of medical records. Binary logistic regression analysis was done to identify factors associated with utilization and optimal dosing of ACEIs. Results. A total of 308 patients were included in the final analysis of this study. The mean (±standard deviation) age of the patients was 52.3 ±15.5 years. Out of the total, 74.7% of the patients were receiving ACEIs. Among the patients who were receiving ACEIs, only 35.7% were taking optimal dose. New York Heart Association (NYHA) class III (Adjusted odds ratio (AOR):0.12, 95% confidence interval (CI):0.02–0.98), valvular heart disease (AOR: 0.27, 95% CI: 0.13-0.56), hypertension (AOR: 5.82, 95% CI: 2.16-15.71), and diabetes mellitus (AOR: 3.84, 95% CI: 1.07-13.86) were significantly associated with the use of ACEIs, whereas age ≥65 (AOR: 2.61, 95%CI: 1.20-5.64), previous hospitalization for heart failure (AOR: 2.08, 95%CI: 1.11-3.92), diuretic use (AOR: 5.60, 95%CI: 2.75-11.40), and dose of furosemide >40mg (AOR: 9.80, 95%CI: 3.00-31.98) were predictors of suboptimal dosing of ACEIs. Conclusion. Although majority of patients were receiving ACEIs, only about one-third were using optimal dosage. Valvular heart disease and NYHA class III were negatively associated with the use of ACEIs while previous hospitalization for heart failure, old age, diuretic use, and diuretic dose were predictors of suboptimal dosing of ACEIs. Therefore, more effort needs to be done to minimize the potentially modifiable risk factors of suboptimal use of ACEIs therapy in heart failure patients.